Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. filed a Form 8-K dated April 21, 2021, under Item 5.02 and Item 9.01. The filing reports adoption of a new Severance Policy for Executives, effective May 1, 2021. The policy was approved by the Board of Directors and applies to eligible executive employees.
Financial Metrics and Capitalization
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial performance metrics.
Material Changes
- The company adopted a formal executive severance policy.
- Eligible executives involuntarily terminated without cause or resigning for good reason may receive severance and continued COBRA premium payments, subject to signing a waiver and release.
- Benefits are based on job tier: 18 months for the CEO, 12 months for other C-level executives and EVPs, nine months for SVPs, and six months for VPs.
- Participants may also receive a pro rata portion of the annual bonus for the termination year, based on actual performance and paid when bonuses are paid to other executive officers.
- The policy applies without duplication of severance benefits under an individual employment agreement; the higher applicable amount would apply.
Outlook, Contingencies, and Unusual Items
- If a qualifying separation occurs within 18 months after a change in control, the participant would receive the pro rata annual bonus based on the target bonus, paid in a lump sum following the release date.
- Following such a change-in-control separation, all unexpired stock options and other unvested time-based equity awards would accelerate and become immediately vested and exercisable.
- Severance benefits are contingent on the applicable termination circumstances and execution of a waiver and release agreement.
- The filing does not provide an estimate of potential future severance, COBRA, bonus, or equity-acceleration costs.
Important Facts for Investors to Verify
- Review Exhibit 10.1 for the complete definitions of cause, good reason, change in control, eligibility, and payment terms.
- Assess which executives are covered and whether individual employment agreements provide more favorable severance terms.
- Consider potential cash obligations and equity dilution or expense effects from future executive departures or a change in control.
- Confirm the policy’s effective date of May 1, 2021 and the filing’s execution date of April 26, 2021.